Tumor suppression activity of adenovirus E1a protein: anoikis and the epithelial phenotype.
Adenovirus E1a proteins reverse-transform diverse human tumor cells in culture. This has stimulated interest in the arenas of clinical and basic cancer research. Clinically, cancer gene therapy trials on E1a are in progress, and drug discovery strategies based on E1a are being considered. Biologically, the effect of E1a is unique in that it overrides most or all oncogenic signaling pathways to yield nontumorigenic cells. Apparently, this is a consequence of the ability of E1a to reprogram transcription in tumor cells so as to produce an epithelial phenotype that is refractory to oncogenic growth stimulation. The molecular basis for this effect is emerging.
Frisch
S M
SM
The Burnham Institute, La Jolla, California 92037, USA.
D017500:Adenovirus E1A Proteins / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use; D023102:Anoikis / Q000502:physiology*; D004848:Epithelium / Q000378:metabolism* / Q000473:pathology; D016147:Genes, Tumor Suppressor; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010641:Phenotype; D014158:Transcription, Genetic
D017500:Adenovirus E1A Proteins